AZ505 ditrifluoroacetate

Name: AZ505 ditrifluoroacetate
Brand: MedChemExpress
SKU: HY-15226A
Rating: 5.0 (22 reviews)

Cat. No.: HY-15226A Purity: 99.91%: FAQs
Data Sheet SDS COA Handling Instructions

AZ505 ditrifluoroacetate is a potent and selective SMYD2 inhibitor with IC₅₀ of 0.12 μM.

For research use only. We do not sell to patients.

AZ505 ditrifluoroacetate Chemical Structure

CAS No. : 1035227-44-1

Size	Price	Stock	Quantity
Solid + Solvent
10 mM * 1 mL in DMSO ready for reconstitution	USD 239	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 239	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 170	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 270	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 390	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 620	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 900	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 22 publication(s) in Google Scholar

Other Forms of AZ505 ditrifluoroacetate:

AZ505 In-stock

19 Publications Citing Use of MCE AZ505 ditrifluoroacetate

: AZ505 ditrifluoroacetate purchased from MedChemExpress. Usage Cited in: Mol Carcinog. 2023 Apr 10. [Abstract]; AZ505 ditrifluoroacetate (AZ505; 20 μM; 48 h) decreases the expression of c-Myc in PC3 and DU145 cells.

: AZ505 ditrifluoroacetate purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Feb 27;9(3):326. [Abstract]; Inhibition of SMYD2 with AZ505 (40 μM, 2 h) decreases the methylation and phosphorylation of STAT3 and p65, but dpes not affect their expression in MDA-MB231 cells.

: AZ505 ditrifluoroacetate purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2017 Jun 30;127(7):2751-2764. [Abstract]; PKD-associated signaling pathways can be affected by SMYD2 in Pkd1 mutant renal epithelial cells and cystic tissues. Western blot analysis of the phosphorylation of ERK, S6, AKT, and Rb as well as the total protein levels of these proteins in Pkd1-null MEK cells with or without AZ505 treatment for 2 hours.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Histone Methyltransferase Isoform Specific Products:

View All Isoforms

EZH1 EZH2 DOT1L SMYD2 SMYD3 SUV39H2/KMT1B EHMT2/G9a/KMT1C EHMT1/GLP/KMT1D SETDB1/KMT2G SETD2/KMT3A SETD7/KMT7 SETD8/KMT5A PRMT1 PRMT3 PRMT4 PRMT5 PRMT6 PRMT7 PRMT8

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

AZ505 ditrifluoroacetate is a potent and selective SMYD2 inhibitor with IC₅₀ of 0.12 μM.

IC₅₀ & Target

IC50: 0.12 μM (SMYD2)^[1]

In Vitro

AZ505 ditrifluoroacetate is highly selective and shows an activity at submicromolar concentrations in vitro. The IC₅₀ of AZ505 ditrifluoroacetate for SMYD2 is 0.12 μM, which is >600-fold greater than the IC₅₀s of AZ505 ditrifluoroacetate for other histone methyltransferases, such as SMYD3 (IC₅₀>83.3 μM), DOT1L (IC₅₀>83.3 μM) and AZ505 ditrifluoroacetate (IC₅₀>83.3 μM)^[1]. AZ505 ditrifluoroacetate is a potent and selective SMYD2 inhibitor with an IC₅₀ of 0.12 μM. The human SMYD (SET and MYND domain-containing protein) family of protein lysine methyltransferases contains five members (SMYD1-5). Moreover, AZ505 ditrifluoroacetate fails to inhibit the enzymatic activities of a panel of protein lysine methyltransferases. AZ505 ditrifluoroacetate is nominated for ITC binding study with K_d of 0.5 μM. In contrast, the calculated K_d for the p53 substrate peptide is 3.7 μM. AZ505 ditrifluoroacetate binding to SMYD2 is driven primarily by entropy, which often suggests that binding is mediated by hydrophobic interactions with few specific hydrogen bonds^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

805.59

Appearance

Solid

Formula

C₃₃H₄₀Cl₂F₆N₄O₈

CAS No.

1035227-44-1

SMILES

O=C(N(C1CCCCC1)CCNCCC2=C(OCC(N3)=O)C3=C(O)C=C2)CCNCCC4=CC=C(Cl)C(Cl)=C4.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 125 mg/mL (155.17 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.2413 mL	6.2066 mL	12.4133 mL
5 mM	0.2483 mL	1.2413 mL	2.4827 mL
10 mM	0.1241 mL	0.6207 mL	1.2413 mL

*Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (2.58 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (2.58 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (2.58 mM); Clear solution

*All of the co-solvents are available by MedChemExpress (MCE).

Purity & Documentation

Purity: 99.91%

Select Batch:

Data Sheet (276 KB) SDS (252 KB)

COA (248 KB) HNMR (223 KB) LCMS (336 KB)

Handling Instructions (2659 KB)

References

[1]. Komatsu S, et al. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer. Br J Cancer. 2015 Jan 20;112(2):357-64. [Content Brief]

[2]. Ferguson AD, et al. Structural basis of substrate methylation and inhibition of SMYD2. Structure. 2011 Sep 7;19(9):1262-73. [Content Brief]

Kinase Assay
^[2]

SMYD2 is expressed in insect cells and purified. AlphaScreen technology is used to screen our chemical library for small molecule inhibitors of SMYD2. Methylation (12 μL) reactions are carried out in TDT buffer (50 mM Tris-HCl [pH 9.0], 2 mM DTT, and 0.01% Tween 20) at room temperature using 1.25 nM SMYD2 protein, 200 nM SAM, and 100 nM biotinylated p53 peptide substrate (Biotin-aminohexanoyl-GSRAHSSHLKSKKGQSTSRH) in low volume 384-well plates. Following a 75 min incubation period, reactions are quenched by the addition of 5 μL of detection solution (20 mM HEPES [pH 7.4], 1.7 mg/mL BSA, 340 mM NaCl, 680 μM SAH, 0.04 mg/mL Streptavidin-coated AlphaScreen donor, and Protein A-coated acceptor beads), and 1 nM of a custom p53K370me1 polyclonal antibody. Reaction plates are incubated overnight in the dark at room temperature, and read using an Envision 2101 Multi-label Reader. Compounds showing >50% inhibition of SMYD2 are nominated for concentration dose-response determination, and are also subjected to an artifact assay. Seven compound concentrations are selected beginning at 30 μM with six half-log dilution steps. The artifact assay conditions are identical to those in the SMYD2 enzymatic activity assay, except for the absence of SMYD2 protein and the presence of 1 nM methylated p53 peptide. IC₅₀ values are calculated from dose-response data using in-house software^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Komatsu S, et al. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer. Br J Cancer. 2015 Jan 20;112(2):357-64. [Content Brief]

[2]. Ferguson AD, et al. Structural basis of substrate methylation and inhibition of SMYD2. Structure. 2011 Sep 7;19(9):1262-73. [Content Brief]